- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-276/16: Judgment of the General Court of 15 September 2017 — Viridis Pharmaceutical v EUIPO — Hecht-Pharma (Boswelan) (EU trade mark — Revocation proceedings — EU word mark Boswelan — Declaration of revocation — Article 51(1)(a) of Regulation (EC) No 207/2009 — No genuine use of the trade mark — No proper reasons for non-use)
ECLI:EU:UNKNOWN:62016TA0276
62016TA0276
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
30.10.2017
Official Journal of the European Union
C 369/12
(Case T-276/16) (<span class="super note-tag">1</span>)
((EU trade mark - Revocation proceedings - EU word mark Boswelan - Declaration of revocation - Article 51(1)(a) of Regulation (EC) No 207/2009 - No genuine use of the trade mark - No proper reasons for non-use))
(2017/C 369/16)
Language of the case: German
Parties
Applicant: Viridis Pharmaceutical Ltd (Tortola, British Virgin Isles) (represented by: C. Spintig, S. Pietzcker and M. Prasse, lawyers)
Defendant: European Union Intellectual Property Office (represented by: S. Hanne, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Hecht-Pharma GmbH (Hollnseth, Germany) (represented by: C. Sachs and J. Sachs, lawyers)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 29 February 2016 (Case R 2837/2014-5), relating to revocation proceedings between Hecht-Pharma and Viridis Pharmaceutical.
Operative part of the judgment
The Court:
1.Dismisses the action;
2.Orders Viridis Pharmaceutical Ltd to pay the costs.
(<span class="note">1</span>) OJ C 251, 11.7.2016.